"Immunomedics, Inc., (Nasdaq:IMMU) today reported that 71% of patients (34 of 48) with diverse metastatic solid cancers had durable disease stabilization after receiving treatments with the Company's novel investigational antibody-drug conjugate (ADC), IMMU-132. These include 7 patients (15%) with colorectal, small-cell and non-small-cell lung, esophageal, and triple-negative breast cancers showing partial responses with tumor shrinkage of 30% or more as measured by computed tomography (CT)."
Editor's note: Scientists have developed a new cancer drug called IMMU-132, which may work in a variety of cancer types. IMMU-132 is an immunotherapy, meaning it boosts a patient's own immune system to fight cancer. A clinical trial to test the drug in volunteer patients found promising results, including in non-small cell lung cancer (NSCLC) patients.